HAYWARD, Calif.--(BUSINESS WIRE)--RefleXion Medical, a theranostic oncology company, today announced the appointment of Steve Schoch as chief financial officer (CFO) and the promotion of Phil Aulson ...

The RefleXion X1 is a dual-treatment modality platform that delivers both SCINTIX biology-guided radiotherapy for lung and bone tumors, and conventional image-guided radiotherapy for solid tumors ...

Targeted radiotherapy company RefleXion Medical has raised $80 million to help broaden its cancer offerings after recently exploring the company’s potential in treating prostate cancer and other ...

Just over a year after being recognized by the FDA for the potential “breakthrough” nature of its radiation therapy technology, RefleXion Medical has gotten the go-ahead from the agency to begin ...

HAYWARD, Calif.--(BUSINESS WIRE)--RefleXion Medical, Inc., a therapeutic oncology company, today announced that results of a prospective investigator-initiated clinical imaging study conducted on its ...

RefleXion Medical announces the initiation of the BIOGUIDE-X2 clinical study to expand indications for SCINTIX® biology-guided radiotherapy. In addition, starting this year, CMS will provide broader ...

What if you could take cancer’s natural activity in the human body and turn it back on itself? That’s the premise behind RefleXion, which made its debut at last week’s ASTRO Annual Meeting with a ...